Phaseline

Targets › ULBP5

ULBP5 (UL-16 binding protein 5): drug programs, companies and trials

1 program from 1 company in 2 trials: 2 Phase 1; Oncology; next expected readout Dec 2026.

[Isoform 1]: Binds and activates the KLRK1/NKG2D receptor, mediating natural killer cell cytotoxicity..; FUNCTION: [Isoform 3]: Down-regulates the expression of KLRK1 and stimulates natural killer cells to secrete IFNG..; FUNCTION: [Isoform 2]: Stimulates natural killer cells to secrete IFNG. (UniProt, Q6H3X3)

Open in Phaseline: the race on ULBP5, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Zhejiang UniversityNKG2D CAR-NK cells
NKG2D-targeted chimeric antigen receptor natural killer cells recognizing NKG2D ligands
ULBP1, ULBP2, ULBP3, ULBP4, ULBP5Phase 1Patients With Advanced Solid Tumors With Liver Metastases Who Have Failed Standard TreatmentsDec 2026

Conditions

Patients With Advanced Solid Tumors With Liver Metastases Who Have Failed Standard Treatments (2)

Modalities

other (1)

Companies

Zhejiang University (1)

Related targets

ULBP1 (1) ULBP2 (1) ULBP3 (1) ULBP4 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.